Sanofi's Chattem Acquires Over-the-Counter Antacid Rolaids®

         Sanofi's Chattem Acquires Over-the-Counter Antacid Rolaids®

-- Product acquisition further strengthens Consumer Healthcare Division of
Sanofi US --

PR Newswire

PARIS, Jan. 7, 2013

PARIS, Jan. 7, 2013 /PRNewswire/ --Sanofi (EURONEXT: SANand NYSE: SNY)
today announced that its US Consumer Healthcare Division, Chattem, Inc.,
completed the acquisition of the worldwide rights to the Rolaids^® brand from
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

"The addition of Rolaids represents a rare opportunity to obtain an iconic
brand that we believe will respond positively to our proven approach of
growing brands through innovation and advertising," said Zan Guerry, Chief
Executive Officer, Chattem. "We are primed to leverage the Rolaids market
opportunity to drive incremental growth and take the brand to a new level."

Rolaids is an over-the-counter antacid that helps relieve heartburn and acid
indigestion. The product was first introduced in 1954 and over the years it
has been a top selling gastro‐intestinal category brand. Chattem will
re-launch Rolaids and expects the product to be available at retailers within
a year.

"This acquisition is consistent with our long-term strategy, which includes
growing our consumer healthcare offering as part of a broader diversification
strategy," said Anne Whitaker, President, North America Pharmaceuticals,
Sanofi. "Chattem has a proven track record of successful acquisitions and
integrations and the addition of Rolaids, an enduring brand with a deep
heritage, further diversifies the company's portfolio."

In 2008, Sanofi identified consumer healthcare as a core growth platform for
the company and subsequently acquired Chattanooga, Tennessee-based Chattem in
March 2010. The acquisition of Chattem provided Sanofi with a presence in the
U.S. consumer healthcare market, which represents 25 percent of the current
worldwide market. In the Spring of 2011, Chattem and Sanofi launched Allegra
over-the-counter (OTC) in what has proven to be one of the most successful OTC
launches in the U.S. 

In addition to Allegra^®, Chattem's portfolio of consumer healthcare brands
includes Icy Hot^®, Gold Bond^®, Cortizone-10^®, Selsun Blue^®, ACT^® and
Unisom^®.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer
healthcare, emerging markets and animal health. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.

Contacts:
Sanofi
Media Relations            Investor Relations
Marisol Peron       Sebastien Martel
Tel. : + (33) 1 53 77 45 02        Tel. : + (33) 1 53 77 45
                                                      45
marisol.peron@sanofi.com             ir@sanofi.com
Media Relations     Investor Relations
Jack                                                  George Grofik
Cox
Tel.: 908 981                                         Tel.: 908 981 6031
5280
Jack.cox@sanofi.com       George.grofik@sanofi.com

SOURCE Sanofi